Literature DB >> 27089415

CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.

Khalil Eldeeb, Sandra Leone-Kabler, Allyn C Howlett.   

Abstract

BACKGROUND: CB1 cannabinoid receptors (CB1Rs) stimulate Gi/o-dependent signaling pathways. CB1R-mediated cAMP increases were proposed to result from Gs activation, but CB1R-stimulated GTPγS binding to Gs has not heretofore been investigated.
METHODS: Three models of CB1R-stimulated cAMP production were tested: pertussis toxin disruption of Gi/o in N18TG2 cells; L341A/A342L-CB1R expressed in Chinese hamster ovary (CHO) cells; and CB1 and D2 dopamine receptors endogenously co-expressed in MN9D cells. cAMP was assayed by [3H]cAMP binding competition. G protein activation was assayed by the antibody-targeted scintillation proximity assay.
RESULTS: In L341A/A342L-CB1-CHO cells, cannabinoid agonists significantly stimulated cAMP accumulation over vehicle; (-)-3-[2-hydroxyl-4-(1,1-dimethylheptyl)phenyl]-4-[3-hydroxyl propyl] cyclohexan-1-ol (CP55940)-stimulated [35S]GTPγS binding to Gi1/2/3 was reversed, whereas binding to Gs was not different from CB1R. In MN9D cells, CB1 agonist HU210 or D2 agonist quinpirole alone inhibited forskolin-activated cAMP accumulation, whereas HU210 plus quinpirole increased cAMP accumulation above basal. HU210 alone stimulated [35S]GTPγS binding to Gi1/2/3, whereas co-stimulation with quinpirole reversed HU210-stimulated [35S]GTPγS binding to Gi1/2/3.
CONCLUSIONS: CB1R couples to Gs but with low efficacy compared to Gi/o. The L341A/A342L mutation in CB1R reversed CP55940 activation of Gi to an inhibition, but had no effect on Gs. Combined CB1 plus D2 agonists in MN9D cells converted the CB1 agonist-mediated activation of Gi to inhibition of Gi. In these models, the CB1 agonist response was converted to an inverse agonist response at Gi activation. Cannabinoid agonist-stimulated cAMP accumulation can be best explained as reduced activation of Gi, thereby attenuating the tonic inhibitory influence of Gi on the major isoforms of adenylyl cyclase.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27089415      PMCID: PMC5497837          DOI: 10.1515/jbcpp-2015-0096

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  48 in total

Review 1.  Principles: extending the utility of [35S]GTP gamma S binding assays.

Authors:  Graeme Milligan
Journal:  Trends Pharmacol Sci       Date:  2003-02       Impact factor: 14.819

Review 2.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

3.  Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?

Authors:  Christopher S Kearn; Katherine Blake-Palmer; Emma Daniel; Ken Mackie; Michelle Glass
Journal:  Mol Pharmacol       Date:  2005-02-14       Impact factor: 4.436

4.  Scintillation proximity assay.

Authors:  Steven D Kahl; Christian C Felder
Journal:  Curr Protoc Neurosci       Date:  2005-02

5.  LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.

Authors:  C C Felder; K E Joyce; E M Briley; M Glass; K P Mackie; K J Fahey; G J Cullinan; D C Hunden; D W Johnson; M O Chaney; G A Koppel; M Brownstein
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

6.  Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions.

Authors:  Somnath Mukhopadhyay; Allyn C Howlett
Journal:  Mol Pharmacol       Date:  2005-03-04       Impact factor: 4.436

7.  Effects of glial cell line-derived neurotrophic factor on microRNA expression in a 6-hydroxydopamine-injured dopaminergic cell line.

Authors:  Li Li; Huizhen Chen; Fangfang Chen; Feng Li; Meng Wang; Li Wang; Yunqing Li; Dianshuai Gao
Journal:  J Neural Transm (Vienna)       Date:  2013-06-16       Impact factor: 3.575

8.  D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor.

Authors:  A Jarrahian; V J Watts; E L Barker
Journal:  J Pharmacol Exp Ther       Date:  2003-11-21       Impact factor: 4.030

Review 9.  Cannabinoid physiology and pharmacology: 30 years of progress.

Authors:  Allyn C Howlett; Christopher S Breivogel; Steven R Childers; Samuel A Deadwyler; Robert E Hampson; Linda J Porrino
Journal:  Neuropharmacology       Date:  2004       Impact factor: 5.250

Review 10.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

View more
  11 in total

1.  Gαs signalling of the CB1 receptor and the influence of receptor number.

Authors:  David B Finlay; Erin E Cawston; Natasha L Grimsey; Morag R Hunter; Anisha Korde; V Kiran Vemuri; Alexandros Makriyannis; Michelle Glass
Journal:  Br J Pharmacol       Date:  2017-06-19       Impact factor: 8.739

2.  Mouse Neuroblastoma CB1 Cannabinoid Receptor-Stimulated [35S]GTPɣS Binding: Total and Antibody-Targeted Gα Protein-Specific Scintillation Proximity Assays.

Authors:  Khalil Eldeeb; Sandra Leone-Kabler; Allyn C Howlett
Journal:  Methods Enzymol       Date:  2017-07-19       Impact factor: 1.600

3.  Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury.

Authors:  Jérémie Joffre; Che-Chung Yeh; Erika Wong; Mayuri Thete; Fengyun Xu; Ivana Zlatanova; Elliot Lloyd; Lester Kobzik; Matthieu Legrand; Judith Hellman
Journal:  J Immunol       Date:  2020-05-08       Impact factor: 5.422

4.  Axonal CB1 Receptors Mediate Inhibitory Bouton Formation via cAMP Increase and PKA.

Authors:  Jian Liang; Dennis L H Kruijssen; Aniek C J Verschuuren; Bas J B Voesenek; Feline F W Benavides; Maria Sáez Gonzalez; Marvin Ruiter; Corette J Wierenga
Journal:  J Neurosci       Date:  2021-08-19       Impact factor: 6.167

5.  CB1 cannabinoid receptor-phosphorylated fourth intracellular loop structure-function relationships.

Authors:  Khalil Eldeeb; Anjali D Ganjiwale; Indu R Chandrashekaran; Lea W Padgett; Jason Burgess; Allyn C Howlett; Sudha M Cowsik
Journal:  Pept Sci (Hoboken)       Date:  2018-12-14

Review 6.  Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease.

Authors:  Debra A Kendall; Guillermo A Yudowski
Journal:  Front Cell Neurosci       Date:  2017-01-04       Impact factor: 5.505

Review 7.  Cannabinoid Receptor Interacting Protein 1a (CRIP1a): Function and Structure.

Authors:  William T Booth; Noah B Walker; W Todd Lowther; Allyn C Howlett
Journal:  Molecules       Date:  2019-10-12       Impact factor: 4.411

Review 8.  A proposed modulatory role of the endocannabinoid system on adipose tissue metabolism and appetite in periparturient dairy cows.

Authors:  Madison N Myers; Maya Zachut; Joseph Tam; G Andres Contreras
Journal:  J Anim Sci Biotechnol       Date:  2021-03-05

9.  Optimization of the Heterologous Expression of the Cannabinoid Type-1 (CB1) Receptor.

Authors:  Viktória B Horváth; Eszter Soltész-Katona; Éva Wisniewski; Anikó Rajki; Eszter Halász; Balázs Enyedi; László Hunyady; András Dávid Tóth; Gergő Szanda
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-20       Impact factor: 5.555

Review 10.  CB1 Cannabinoid Receptor Signaling and Biased Signaling.

Authors:  Luciana M Leo; Mary E Abood
Journal:  Molecules       Date:  2021-09-06       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.